NCT04567784 - Neuroimaging and CBD for Opioid Use Disorder | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

November 12, 2020

Primary Completion Date

November 12, 2025

Study Completion Date

November 12, 2025

Conditions

Heroin AbuseOpioid Use DisorderSubstance-Related DisordersOpioid-Related Disorders

Interventions

DRUG

Cannabidiol (CBD)

CBD 800 mg Cannabidiol - oral CBD solution

DRUG

Placebo

inactive solution

Trial Locations (1)

Icahn School of Medicine at Mount Sinai, New York